Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis’ Scemblix gains FDA approval for leukaemia

Novartis Reports Strong Q3 Growth and Raises Guidance

Novartis AG (NVS) Q3 2024 Earnings Call Highlights: Record Cash Flow and Robust Sales Growth

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis Stock Dives on $800 Million Write-Down

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript